Claims for Patent: 9,161,992

Summary for Patent: 9,161,992

Title:	P97 fragments with transfer activity
Abstract:	The present invention is related to fragments of human melanotransferrin (p97). In particular, this invention relates to treatment of diseases through the introduction of the melanotransferrin fragment conjugated to a therapeutic or diagnostic agent to a subject.
Inventor(s):	Jefferies; Wilfred (South Surrey, CA), Tian; Mei Mei (Coquitlam, CA), Vitalis; Timothy (Vancouver, CA)
Assignee:	biOasis Technologies, Inc. (British Columbia, CA)
Application Number:	14/226,506
Patent Claims:	1. A conjugate, comprising a p97 polypeptide that consists of at least one of SEQ ID NO:1-8 or 9 or a sequence having at least 95% identity along its length to SEQ ID NO:1-8 or 9 or a sequence that differs from SEQ ID NO:1-8 or 9 by the addition or deletion of about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 N-terminal and/or C-terminal residues, where the p97 polypeptide is covalently or operatively linked to (a) etanercept or an antigen-binding fragment or variant thereof that specifically binds to tumor necrosis factor (TNF)-.alpha., or (b) an antibody or antigen-binding fragment thereof that specifically binds to amyloid-.beta.(A.beta.). 2. The conjugate of claim 1, where the p97 polypeptide is covalently or operatively linked to etanercept or an antigen-binding fragment or variant thereof that specifically binds to TNF-.alpha.. 3. The conjugate of claim 2, where the p97 polypeptide is covalently or operatively linked to etanercept. 4. The conjugate of claim 1, where the p97 polypeptide is covalently or operatively linked to an antibody or antigen-binding fragment thereof that specifically binds to amyloid-.beta.(A.beta.). 5. The conjugate of claim 4, where the antibody or antigen-binding fragment thereof specifically binds to A.beta..sub.(1-42). 6. The conjugate of claim 1, where the p97 polypeptide is covalently linked to (a) or (b). 7. The conjugate of claim 6, where the p97 polypeptide is covalently linked to (a) or (b) via a linker. 8. The conjugate of claim 7, where the linker comprises a polyethylene glycol. 9. The conjugate of claim 6, where the p97 polypeptide is fused to (a) or (b) to form a fusion protein. 10. The conjugate of claim 8, where the fusion protein comprises a peptide linker. 11. A pharmaceutical composition, comprising a conjugate of claim 1 and a pharmaceutically acceptable carrier. 12. A method of treating a subject in need thereof, comprising administering to the subject a pharmaceutical composition of claim 10. 13. The method of claim 11, for treating a degenerative or autoimmune disorder of the central nervous system (CNS). 14. The method of claim 12, where the degenerative or autoimmune disorder of the CNS is Alzheimer's disease, Huntington's disease, Parkinson's disease, or multiple sclerosis (MS). 15. The method of claim 11, for treating pain, or a nervous system or autoimmune disorder. 16. The method of claim 14, for treating Alzheimer's disease, stroke, traumatic brain injury (TBI), spinal stenosis, acute spinal cord injury, or spinal cord compression.

Details for Patent 9,161,992

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2031-08-05
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2031-08-05
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2031-08-05
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007		2031-08-05
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	09/14/2017		2031-08-05
Immunex Corporation	ENBREL	etanercept	Injection	103795			2031-08-05